Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Neuronlcon

2006 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
Description

Developer of receptor technologies for neurological disorders. The company offers therapies for the treatment of brain damage and other brain related diseases such as stroke, spinal cord injuries and Alzheimer's and Parkinson's diseases.

Ownership Status
Acquired/Merged
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Other Healthcare Technology Systems
Acquirer
Primary Office
  • Gustav Wieds Vej 10
  • 8000 Århus
  • Denmark

+45 28 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Neuronlcon’s full profile, request a free trial.

Neuronlcon Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 07-Jul-2009 Completed Startup
1. Early Stage VC 01-Jan-2006 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Neuronlcon Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Capnova Venture Capital Minority 000 0000 000000 0

Neuronlcon Executive Team (1)

Name Title Board
Seat
Contact
Info
Anders Nykjaer Ph.D Chief Executive Officer & Co-Founder